Bacterial Vaginosis-Associated Bacterium 2 (BVAB2)

If you've been treated for bacterial vaginosis (BV) and the odor or discharge keeps coming back, the first question is whether the bacteria behind it ever left. BVAB2 (bacterial vaginosis-associated bacterium 2) is one of the more useful organisms to look for, because it rarely turns up in meaningful amounts unless the vaginal community has already shifted toward BV. That makes it a good marker for confirming BV and for checking whether it has cleared.

It can also show up before symptoms do. In one group of women followed over time, those who carried it while still free of BV went on to develop BV at many times the rate of those who didn't. This is an emerging marker without standard cutoffs, and labs measure it in different ways, so it reads best alongside the other organisms on your panel and tracked over time.

What BVAB2 Is

BVAB2 is a bacterium. Researchers found it by reading bacterial DNA from women with BV, and it still hasn't been grown in a lab dish, so every measurement of it comes from detecting its genetic material. It belongs to a large group of bacteria that live without oxygen, the order Clostridiales.

A healthy vagina is usually dominated by Lactobacillus species, especially Lactobacillus crispatus, which make lactic acid and keep the environment acidic. When those lactobacilli thin out, the acidity drops and a mixed crowd of oxygen-avoiding bacteria moves in. That mixed state is BV, and BVAB2 is one of the organisms that thrives in it.

BVAB2 usually arrives after the shift has started. Current models put organisms like Gardnerella first, laying down a sticky bacterial film on the vaginal lining, with BVAB2 and other latecomers growing inside it once conditions have changed. So a high level means the imbalance is already well established, with BVAB2 as one member of a larger community.

How Well It Picks Out BV

Specificity is BVAB2's main strength: when it's present in quantity, BV is very likely. In the study that first identified it by DNA, it turned up in most women with BV and only rarely in women without it.

Its weakness is that plenty of women with BV carry little or none of it. A study of 288 swabs found it correctly cleared every woman without BV across several cutoffs, but caught only half to six in ten of those who had it. That's why labs pair it with other organisms, and the gain from doing so is large.

Sources: Deng et al. (rows 1 and 2); Cartwright et al. (row 3).

What this means for you: a high BVAB2 result is a strong clue, but a low one on its own doesn't rule BV out. Read it together with your lactobacillus and Gardnerella results, because the combination is far more accurate than any single organism.

Sorting Out Borderline Results

The classic lab method for BV is the Nugent score. A technician stains a slide of vaginal fluid, counts bacterial shapes under a microscope, and places you in normal, BV, or an in-between intermediate group. Reading the slide depends on the person doing it, and the intermediate group leaves a sizable share of women without a clear answer.

In-clinic exams use the Amsel criteria, a checklist of signs such as discharge, odor, and pH. Compared with DNA-based panels, in-clinic assessment missed a substantial share of cases in several studies. In one study, a DNA panel that included BVAB2 sorted many intermediate Nugent slides into a clear BV or non-BV result, which gives you an answer you can act on.

A Signal Before Symptoms

In a cohort of women who have sex with women, those who carried BVAB2 at the start without having BV developed BV at a much higher rate than women who didn't carry it. In a related cohort, women who went on to get BV were also more likely to carry BV bacteria outside the vagina, including the rectum, which suggests the vagina can be reseeded from nearby reservoirs. This finding comes from one specific population and hasn't been confirmed broadly.

What this means for you: a detectable level with no symptoms isn't a diagnosis, and no trial has shown that treating it at that stage changes outcomes. It is a good reason to retest in a few weeks and watch which direction it's heading, especially if you've had BV before.

Sex, Partners, and Spread

BVAB2 is closely tied to sexual exposure. In a study of 339 women, unprotected penile-vaginal sex strongly predicted finding it, and it was rare or absent in women who had never had sex. In the women-who-have-sex-with-women cohort above, acquiring BV was also linked to a new partner who had BV.

Men can carry it too. In 317 men who have sex with women, BVAB2 in the urethra was not linked to urethritis, so men who carry it usually have no symptoms of their own. A separate study of 75 women treated for BV, which tracked the overall vaginal community rather than BVAB2 specifically, found that sex with an untreated regular partner after antibiotics was linked to the community sliding back toward BV.

Pregnancy, Fertility, and Infection Risk

Most of what's known here comes from studies of BV as a condition, diagnosed by microscope or exam, rather than from measuring BVAB2 itself. A meta-analysis tied BV to preterm birth. In 924 pregnant women, BV in early pregnancy roughly tripled the risk of infection of the uterine lining after delivery, a condition called postpartum endometritis.

BV has also been linked to taking longer to conceive in Kenyan women planning a pregnancy, and to very early pregnancy loss, though not first-trimester miscarriage, in women being treated for infertility. In a study of African couples, BV in the woman was tied to more than three times the risk of passing HIV to a male partner.

BVAB2 can travel upward. In 58 women having a hysterectomy, it was found in the uterine lining and cervix at levels 100 to 10,000 times lower than in the vagina, and those low levels of bacteria in the uterus weren't tied to significant inflammation.

Screening is where expectations and data part ways. In a randomized trial of 6,671 low-risk pregnant women, DNA-based screening for BV followed by treatment didn't significantly reduce preterm birth, and a review for the US Preventive Services Task Force reached the same conclusion for screening pregnant women without symptoms. A look at women in their first pregnancy suggested a possible benefit, but that analysis was done after the fact and needs confirmation.

Both sets of findings can be true at once. BV marks a vaginal environment that travels with higher risk, but finding and treating it in a healthy, low-risk pregnancy without symptoms hasn't been shown to change how that pregnancy turns out. The marker is most useful when you have symptoms, recurrences, or a treatment you want to confirm worked; for women with a prior preterm birth, the evidence is still inconclusive and worth discussing with an obstetrician.

Why One Swab Isn't Enough

Vaginal bacteria move around. Studies that sampled women daily or weekly, tracking the vaginal community broadly rather than BVAB2 alone, found levels swinging over a single month, with shifts tied to the menstrual cycle and to sex. BV also comes back often, and after antibiotics the same bacteria frequently reappear when it does.

A series of results tells you far more than one. If you're being treated, swab before treatment, again a few weeks after you finish, and again around three months later, since that's the window where relapse tends to show up. If you're healthy, a baseline gives you something to compare against, and a retest makes sense with a new partner or new symptoms. Use the same lab and panel each time, because numbers from different panels don't line up.

When Results Can Be Misleading

Most surprises come from timing and from how the lab reports the number.

• Your menstrual cycle: vaginal bacteria shift across the cycle, and menstruation raises Gardnerella in particular, so a swab taken during or right after your period may not reflect your usual state.
• Recent antibiotics: a recent course can push BV bacteria down for a while before they return, so a swab taken right after treatment can look better than where you'll settle.
• Recent sex: sexual activity is one of the factors linked to short-term swings in the vaginal community.
• Low-level detection and lab differences: small amounts of BVAB2 can show up in women without BV, and studies that applied a quantity threshold made the result more specific for BV. Panels also differ in which organisms they include and how they report results. Because BVAB2 has never been grown in culture, any number on your report is derived from DNA signal rather than counted colonies, so results from different labs aren't directly comparable.

Occasionally, sample handling or lab factors can affect the result, which is one more reason to confirm a surprise with a repeat swab.

What to Do With an Unexpected Result

High BVAB2 with depleted lactobacilli and high Gardnerella or Atopobium, especially with odor or discharge, makes BV likely. Treatment is a prescription, so this is the point to bring in a clinician. Check for trichomonas, chlamydia, and gonorrhea at the same time, since women tested for sexually transmitted infections often have BV alongside them, and yeast can turn up as a co-infection too.

A detectable level with no symptoms and a lactobacillus-dominated panel calls for a repeat swab in a few weeks rather than treatment. If the level climbs, or the lactobacilli start to fall, the pattern is moving toward BV.

A level that stays high after treatment means treatment probably didn't clear it. That's worth a visit to a gynecologist or a clinic that manages recurrent BV, and a conversation about whether a regular partner may be reseeding you. If you're pregnant or planning to be and have had a preterm birth, bring your results to your obstetrician.